Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds

A. R M Ruhul Amin, Phillip A. Karpowicz, Thomas E. Carey, Jack Arbiser, Rita Nahta, Zhuo G. Chen, Jin Tang Dong, Omer Kucuk, Gazala N. Khan, Gloria S. Huang, Shijun Mi, Ho Young Lee, Joerg Reichrath, Kanya Honoki, Alexandros G. Georgakilas, Amedeo Amedei, Amr Amin, Bill Helferich, Chandra S. Boosani, Maria Rosa CirioloSophie Chen, Sulma I. Mohammed, Asfar S. Azmi, W. Nicol Keith, Dipita Bhakta, Dorota Halicka, Elena Niccolai, Hiromasa Fujii, Katia Aquilano, S. Salman Ashraf, Somaira Nowsheen, Xujuan Yang, Alan Bilsland, Dong M. Shin

Research output: Contribution to journalArticle

Abstract

The evasion of anti-growth signaling is an important characteristic of cancer cells. In order to continue to proliferate, cancer cells must somehow uncouple themselves from the many signals that exist to slow down cell growth. Here, we define the anti-growth signaling process, and review several important pathways involved in growth signaling: p53, phosphatase and tensin homolog (PTEN), retinoblastoma protein (Rb), Hippo, growth differentiation factor 15 (GDF15), AT-rich interactive domain 1A (ARID1A), Notch, insulin-like growth factor (IGF), and Krüppel-like factor 5 (KLF5) pathways. Aberrations in these processes in cancer cells involve mutations and thus the suppression of genes that prevent growth, as well as mutation and activation of genes involved in driving cell growth. Using these pathways as examples, we prioritize molecular targets that might be leveraged to promote anti-growth signaling in cancer cells. Interestingly, naturally occurring phytochemicals found in human diets (either singly or as mixtures) may promote anti-growth signaling, and do so without the potentially adverse effects associated with synthetic chemicals. We review examples of naturally occurring phytochemicals that may be applied to prevent cancer by antagonizing growth signaling, and propose one phytochemical for each pathway. These are: epigallocatechin-3-gallate (EGCG) for the Rb pathway, luteolin for p53, curcumin for PTEN, porphyrins for Hippo, genistein for GDF15, resveratrol for ARID1A, withaferin A for Notch and diguelin for the IGF1-receptor pathway. The coordination of anti-growth signaling and natural compound studies will provide insight into the future application of these compounds in the clinical setting.

Original languageEnglish
JournalSeminars in Cancer Biology
DOIs
Publication statusAccepted/In press - 2015

    Fingerprint

Keywords

  • Anti-growth signaling
  • Cancer prevention
  • Hallmark of cancer
  • Reversible and irreversible evasion
  • Tumor suppressor

ASJC Scopus subject areas

  • Cancer Research

Cite this

Amin, A. R. M. R., Karpowicz, P. A., Carey, T. E., Arbiser, J., Nahta, R., Chen, Z. G., Dong, J. T., Kucuk, O., Khan, G. N., Huang, G. S., Mi, S., Lee, H. Y., Reichrath, J., Honoki, K., Georgakilas, A. G., Amedei, A., Amin, A., Helferich, B., Boosani, C. S., ... Shin, D. M. (Accepted/In press). Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. Seminars in Cancer Biology. https://doi.org/10.1016/j.semcancer.2015.02.005